fda compounding semaglutide crackdown news today proposes a new GLP-1 Report: FDA must enforce rules

For oral semaglutide (Rybelsus), the FDA prescribing information specifically notes increased thyroxine exposure when co-administered with levothyroxine

If you want a telehealth GLP-1 program with direct provider access, transparent pricing, and personalized support, Independent Wellness is built for that experience

This is why the protein recommendation for Retatrutide sits at the top of the range

Other options may be preferable for people who: Prefer FDA-approved finished drug products: If having an FDA-approved finished product is important to you, compounded formulations - from any platform - may not align with your preferences